Cybrexa Therapeutics Is A Clinical Stage Biotechnology Company Based In New Havenconnecticutfounded In 2017The Company Focuses On Developing Innovative Cancer Therapeutics Using Its Proprietary Alphalexa C Technology Platformthis Platform Employs Ph Low Insertion Peptidesphlipa To Deliver Drugs Selectively To Tumorsindependent Of Antigen Expressionwhich Addresses Some Limitations Of Current Cancer Therapies Cybrexa S Pipeline Features Peptide Drug Conjugatespdcstargeting Various Tumor Typesincluding Breastovariannon Small Cell Lung Cancerand Colorectal Cancersthe Company Has Made Significant Progress With Preclinical And Clinical Stage Assetsincluding Promising Phase 1 Resultsa Notable Collaboration With Exelixis In 2022 Highlights The Potential Of Its Lead Productcbx 12Which Aims To Provide First In Class Therapiescybrexa Is Committed To Improving Patient Outcomes By Overcoming Biological Barriers In Cancer Treatment
